Jan Wehkamp mainly investigates Defensin, Immunology, Microbiology, Inflammatory bowel disease and Antimicrobial peptides. Jan Wehkamp interconnects Proinflammatory cytokine, Beta-defensin 2, Antibacterial agent and Tumor necrosis factor alpha in the investigation of issues within Defensin. The various areas that Jan Wehkamp examines in his Microbiology study include Probiotic and Bacteria.
His biological study spans a wide range of topics, including Crohn's disease, Receptor and Ulcerative colitis. Jan Wehkamp focuses mostly in the field of Crohn's disease, narrowing it down to topics relating to Paneth cell and, in certain cases, Pathogenesis and NOD2. His Antimicrobial peptides study combines topics from a wide range of disciplines, such as Innate immune system, Intestinal mucosa and Pathology.
Jan Wehkamp spends much of his time researching Immunology, Microbiology, Defensin, Crohn's disease and Antimicrobial peptides. His study in Immunology is interdisciplinary in nature, drawing from both Paneth cell and Inflammatory bowel disease. In his study, which falls under the umbrella issue of Inflammatory bowel disease, Colitis is strongly linked to Ulcerative colitis.
His work on Antimicrobial as part of general Microbiology study is frequently connected to Mucus, therefore bridging the gap between diverse disciplines of science and establishing a new relationship between them. The study incorporates disciplines such as Proinflammatory cytokine, Molecular biology, Intestinal mucosa and Probiotic in addition to Defensin. The various areas that he examines in his Crohn's disease study include Gastroenterology, Small intestine and Intensive care medicine.
His primary scientific interests are in Microbiology, Disease, Crohn's disease, Antimicrobial and Inflammatory bowel disease. He has included themes like Experimental colitis and Peptide in his Microbiology study. His Disease study incorporates themes from Dermatology, Wnt signaling pathway and Tumor necrosis factor alpha, Immunology.
His Immunology research integrates issues from Oral administration and Cancer research. The concepts of his Antimicrobial study are interwoven with issues in Paneth cell, Cell biology and Bacteria. His Inflammatory bowel disease research is multidisciplinary, incorporating perspectives in Gastroenterology, Psychiatry and Ulcerative colitis.
His primary areas of investigation include Crohn's disease, Inflammatory bowel disease, Antimicrobial peptides, Internal medicine and Ulcerative colitis. The study incorporates disciplines such as Surgery, Endoscopy and Natural course in addition to Crohn's disease. His Inflammatory bowel disease study combines topics from a wide range of disciplines, such as Concomitant and Colitis.
His Antimicrobial peptides research is multidisciplinary, relying on both Defensin, Paneth cell, Immunology and Cell biology. His study in Defensin is interdisciplinary in nature, drawing from both Lipopolysaccharide, Innate immune system and Akkermansia. Jan Wehkamp combines subjects such as Gastroenterology and Endocrinology with his study of Internal medicine.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial
Wolfgang Hueber;Bruce E Sands;Steve Lewitzky;Marc Vandemeulebroecke.
Reduced Paneth cell α-defensins in ileal Crohn's disease
Jan Wehkamp;Nita H. Salzman;Edith Porter;Edith Porter;Sabine Nuding.
Proceedings of the National Academy of Sciences of the United States of America (2005)
NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal alpha-defensin expression.
J. Wehkamp;J. Harder;M. Weichenthal;M. Schwab.
A chromosome 8 gene-cluster polymorphism with low human beta-defensin 2 gene copy number predisposes to Crohn disease of the colon.
Klaus Fellermann;Daniel E. Stange;Elke Schaeffeler;Hartmut Schmalzl.
American Journal of Human Genetics (2006)
NF-κB- and AP-1-Mediated Induction of Human Beta Defensin-2 in Intestinal Epithelial Cells by Escherichia coli Nissle 1917: a Novel Effect of a Probiotic Bacterium
Jan Wehkamp;Jürgen Harder;Kai Wehkamp;Birte Wehkamp-von Meissner.
Infection and Immunity (2004)
Reduction of disulphide bonds unmasks potent antimicrobial activity of human β-defensin 1
Bjoern O. Schroeder;Zhihong Wu;Sabine Nuding;Sabine Nuding;Sandra Groscurth.
Inducible and constitutive β‐defensins are differentially expressed in Crohn's disease and ulcerative colitis
Jan Wehkamp;Juergen Harder;Michael Weichenthal;Oliver Mueller.
Inflammatory Bowel Diseases (2003)
Probiotic lactobacilli and VSL#3 induce enterocyte β-defensin 2
M Schlee;J Harder;B Köten;E F Stange.
Clinical and Experimental Immunology (2008)
NOD2/CARD15 mediates induction of the antimicrobial peptide human beta-defensin-2.
Eske Voss;Jan Wehkamp;Kai Wehkamp;Eduard F. Stange.
Journal of Biological Chemistry (2006)
Induction of Human β-Defensin 2 by the Probiotic Escherichia coli Nissle 1917 Is Mediated through Flagellin
Miriam Schlee;Jan Wehkamp;Jan Wehkamp;Artur Altenhoefer;Tobias A. Oelschlaeger.
Infection and Immunity (2007)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: